Investigating the targeted anti-TNBC ability of small natural compound

Abstract ID 129794 Poster Board 168 Triple-Negative Breast Cancer (TNBC) cells lack hormone receptors for progesterone, estrogen and human epidermal growth-factor which are known targets for chemotherapeutics. This makes TNBC resistant to most chemotherapies. Current treatments for TNBC are toxic to both normal breast tissue and cancerous tissue, resulting in severe side effects. The receptor orphan tyrosine kinase-like receptor-1 (ROR1), an oncofetal protein, has emerged as a target for treatment of TNBC by inhibition. ROR1 is highly expressed in TNBC cells and minimally in normal breast cells, presenting itself as an ideal target for safe and effective treatment. This study focuses on the use of a small natural anti-cancer compound (CPD005) that targets ROR1. The study posits that the compound will be highly potent to TNBC with minimal effects on normal breast cells. To test cell viability and determine IC50, assays that investigate the ability of the compound to inhibit migration and invasion would be utilized. Our preliminary results suggest that CPD005 has an IC50 at low doses for TNBC cells with minimal harm to normal breast cells. Data from this study will lead to establishing the potency of a small natural compound that could potentially be developed as a therapeutic agent for TNBC.